Autoimmune and rare autoimmune diseases are complex and pose challenges for clinical trials. These conditions vary widely in their manifestations and severity, making them difficult to diagnose and treat. Inherent heterogeneity also presents unique difficulties in protocol development, such as developing entry criteria and complex endpoints, recruitment, and retention. While patients often experience a diagnostic odyssey, which causes enormous stress and frustration, new advancements in precision medicine and biomarker-informed decisions are changing our approach.
Read this white paper to learn more about:
- The utility of biomarkers in autoimmune and rare autoimmune disorders
- How to improve recruitment for these complex diseases
- How to ensure adequate and targeted participant representation to best position a potential therapeutic for success in development
